MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

(marketscreener.com) Clinical data on AgenT-797, allogeneic iNKTs, +/- anti-PD-1 in advanced solid tumorsClinical data of AgenT-797 in viral ARDS and refractory multiple myelomaNew therapeutic candidates: 1) MiNK-215, an allo-FAP-CAR-iNKT; 2) MiNK-413, allo-armored-BCMA-CAR-iNKT NEW YORK, Oct. 05, 2022 -- MiNK Therapeutics, Inc., a clinical-stage...https://www.marketscreener.com/quote/stock/MINK-THERAPEUTICS-INC-128249930/news/MiNK-Selected-for-Five-Presentations-at-Society-for-Immunotherapy-of-Cancer-s-SITC-37th-Annual-Mee-41933223/?utm_medium=RSS&utm_content=20221005